Cardiac tumors and thrombi
Cardiac tumors and thrombi is a research topic within Cardiology and Cardiovascular Medicine. Science Explorer counts 29k research works in it since 1950. 6.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the diagnosis, management, and molecular features of cardiac tumors, including primary cardiac neoplasms, left ventricular thrombus, and pulmonary artery sarcoma. It also explores the genetic mutations associated with conditions like the Carney complex and PRKAR1A gene mutations. The papers discuss imaging techniques such as echocardiography and MRI for evaluating cardiac masses and tumors.
- Cardiac Tumors
- PRKAR1A Gene Mutations
- Left Ventricular Thrombus
- Cardiac Imaging
- Primary Cardiac Neoplasms
- Carney Complex
- Pulmonary Artery Sarcoma
- Echocardiography
- Metastatic Cardiac Involvement
- Cardiac Myxomas
- Research works
- 29k fractional, since 1950
- In the world top 10%
- 2k per year above
- Top-10% rate
- 6.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +27% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Cardiac tumors and thrombi research?
By volume, the United States and China publish the most (1.4k and 741 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.4k works
- 2 China 741 works
- 3 Japan 464 works
- 4 India 335 works
- 5 Italy 246 works
- 6 United Kingdom 157 works
- 7 Spain 154 works
- 8 Germany 147 works
- 9 France 119 works
- 10 Türkiye 101 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Cardiac tumors and thrombi research?
By volume in 2022–2025, Cleveland Clinic publishes the most Cardiac tumors and thrombi research, followed by Mayo Clinic in Arizona and Chinese Academy of Medical Sciences & Peking Union Medical College.
By volume, 2022–2025
- 1 Cleveland ClinicUnited States 34 works
- 2 Mayo Clinic in ArizonaUnited States 29 works
- 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 25 works
- 4 All India Institute of Medical SciencesIndia 24 works
- 5 Sichuan UniversityChina 20 works
- 6 The University of Texas MD Anderson Cancer CenterUnited States 19 works
- 7 Mohammed V UniversityMorocco 16 works
- 8 Mayo ClinicUnited States 16 works
- 9 West China Hospital of Sichuan UniversityChina 16 works
- 10 Peking UniversityChina 14 works
Who are the leading researchers in Cardiac tumors and thrombi?
The most-cited researchers publishing on Cardiac tumors and thrombi include Bernard J. Gersh, Patrick W. Serruys and David R. Holmes.
- 1 Bernard J. Gersh United States 4k citations
- 2 Patrick W. Serruys Netherlands 3.6k citations
- 3 David R. Holmes United States 3.2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Cardiac tumors and thrombi research done?
The largest centres of Cardiac tumors and thrombi research in 2022–2025 are Beijing (China), Tokyo (Japan), New York (United States) and London (United Kingdom). Among places with at least 20 works in it, it is an unusually large share of all research in Scottsdale.
Largest cities, 2022–2025
Where it is the local speciality
- ScottsdaleUS · 29.0 works11×
Location quotient: how much more of its research is in Cardiac tumors and thrombi than the world average.
Where is the best place to study Cardiac tumors and thrombi?
Among universities, judged by research, Chinese Academy of Medical Sciences & Peking Union Medical College, All India Institute of Medical Sciences and Kunming Medical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 49.1 | 7.3% | 5.1× | 26 | +69.2% |
| 2 | All India Institute of Medical SciencesIndia | 47.5 | 3.8% | 7.8× | 24 | +49.2% |
| 3 | Kunming Medical UniversityChina | 41.5 | 4.5% | 10.2× | 9 | — |
| 4 | Sichuan UniversityChina | 39.1 | 8.0% | 2.2× | 20 | +94.0% |
| 5 | Harvard UniversityUnited States | 39.1 | 15.2% | 1.4× | 9 | +0.2% |
| 6 | Mohammed V UniversityMorocco | 38.7 | 0.0% | 7.9× | 16 | +40.4% |
| 7 | Baylor College of MedicineUnited States | 36.5 | 8.1% | 4.8× | 10 | +57.0% |
| 8 | Peking UniversityChina | 35.5 | 4.1% | 1.7× | 14 | +233.0% |
| 9 | University of PaduaItaly | 34.1 | 10.1% | 2.6× | 11 | -10.3% |
| 10 | University of California, Los AngelesUnited States | 31.9 | 13.2% | 1.8× | 9 | -9.7% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Cardiac tumors and thrombi research growing?
Output in 2018–2022 was 27% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Cardiac tumors and thrombi.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.